S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.05
$1.10
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
3,873 shs
Average Volume
3,410 shs
Market Capitalization
$4.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IDXG stock logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.


IDXG Stock News Headlines

PDI: 14% Yield, But Risks Are Rising (Rating Downgrade)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
PDI: Lag Likely To Continue
PDI: Pain Could Be On The Horizon
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
PDI And PTY: Unwelcome ROC, Buyer Beware
PTY And PDI: Abysmal Setups
PDI Vs. PDO: Which High-Yielder Is Better?
PDI: More Patience Required
PDI: Utility Maximizing Income Fund
See More Headlines
Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2023
Today
2/28/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
CUSIP
69329V10
Employees
152
Year Founded
N/A

Profitability

Net Income
$-21,960,000.00
Pretax Margin
-2.86%

Debt

Sales & Book Value

Annual Sales
$31.84 million
Cash Flow
$1.19 per share
Book Value
($14.78) per share

Miscellaneous

Free Float
4,071,000
Market Cap
$4.57 million
Optionable
Not Optionable
Beta
0.59
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Thomas W. Burnell Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $425k
  • Mr. Thomas John Freeburg Ph.D. (Age 52)
    Chief Accounting Officer, CFO, Treasurer & Sec.
  • Dr. Sydney D. Finkelstein
    Chief Scientific Officer
  • Dr. Alidad Mireskandari M.B.A.
    Ph.D., Chief Devel. Officer
  • Mr. Patrick Kane
    VP & Corp. Controller














IDXG Stock Analysis - Frequently Asked Questions

When is Interpace Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our IDXG earnings forecast
.

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) announced its earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business services provider earned $8.33 million during the quarter.

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

This page (NASDAQ:IDXG) was last updated on 2/29/2024 by MarketBeat.com Staff